Showing 676 news articles about New & experimental HIV treatments

Filters Content type: Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

Side effects

HIV Drugs With Fewer Side Effects Need More FDA Support

Editor's pick
HivPlusMag.com
27 March 2019
New & experimental HIV treatments

Why 1 Top Analyst Thinks Gilead Sciences Will Soar More Than 25%

Editor's pick
Motley Fool
24 March 2019
New & experimental HIV treatments

Trogarzo’s Effects on Hard-to-Treat HIV Are Stable Over Two Years

Editor's pick
Poz
20 March 2019
New & experimental HIV treatments

HIV Drug Aiming to Free Patients From Daily Doses Nears Market

Editor's pick
Bloomberg
8 March 2019
The search for a cure

Using anti-cancer immunotherapy to fight HIV

Editor's pick
Eurekalert Medicine & Health
20 February 2019
New & experimental HIV treatments

CytoDyn wins key concession from FDA for flagship HIV drug leronlimab trial

Editor's pick
Proactive Investors USA & Canada
4 February 2019
Injectable & long-acting HIV treatment

Emerging options: Doctors and advocates discuss treatment and prevention breakthroughs on the horizon

Editor's pick
Positively Aware
30 January 2019
New & experimental HIV treatments

South Africa: New safety concerns emerge on latest HIV wonder drug

Editor's pick
Business Day
18 January 2019
New & experimental HIV treatments

Dolutegravir monotherapy 'not a valid option' for patients with HIV

Editor's pick
Healio
15 January 2019
Low CD4 count

‘Left behind’: Drug companies and researchers have overlooked patients who don’t respond to HIV meds

Editor's pick
STAT
8 January 2019
Pharmaceutical industry

Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment

Editor's pick
BioPharma Dive
12 December 2018
New & experimental HIV treatments

European Commission Approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine)

Editor's pick
Merch press release
28 November 2018
New & experimental HIV treatments

Tivicay Plus Boosted Prezista Shows Promise as Two-Drug HIV Regimen

Editor's pick
Poz
16 November 2018
Injectable & long-acting HIV treatment

ViiV’s Long-Acting Injectable HIV Regimen Boasts Good 3-Year Results

Editor's pick
Poz
5 November 2018
Starting treatment

Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA in Treatment-Naïve Adults with HIV-1

Editor's pick
Janssen press release
1 November 2018
Starting treatment

Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

Editor's pick
Gilead press release
1 November 2018
New & experimental HIV treatments

Long-lasting HIV injection is a step closer after second GSK study

Editor's pick
Reuters
31 October 2018
New & experimental HIV treatments

ViiV Seeks FDA Approval for Two-Drug HIV Treatment

Editor's pick
Poz
22 October 2018
The search for a cure

Gilead and Aelix join forces to pursue HIV 'cure'

Editor's pick
PMLiVE
18 October 2018
New & experimental HIV treatments

Long-acting injectable implant shows promise for HIV treatment and prevention

Editor's pick
University of North Carolina
9 October 2018
Changing treatment

Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens

Editor's pick
Merck press release
5 October 2018
Changing treatment

Janssen Reports Switching to SYMTUZA™ Results in Maintained High Virologic Suppression and No Resistance Development up to 96-Weeks in Virologically Suppressed Adults with HIV-1

Editor's pick
Janssen press release
5 October 2018
The search for a cure

Vedolizumab could be used to target latent HIV harboring in gut

Editor's pick
Healio
4 October 2018
New & experimental HIV treatments

Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

Editor's pick
Gilead press release
3 October 2018